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Abstract
Objective
Despite frequent use of fingolimod (FTY) and dimethyl fumarate (DMF), studies comparing
clinical efficacy and withdrawal rates of DMF and FTY concerning different pretreatment
situations are rare. The aim of our study was to compare relapse occurrence and withdrawal
rates of DMF and FTY in different pretreatment situations.
Methods
Patients from 4 European centers were retrospectively identified and followed until the 1st
relapse after treatment start or if no relapse occurred for a maximum of 2 years. Cox regression
analyses adjusted for relapsing-remitting MS (RRMS) disease duration, sex, and region were
performed for the following pretreatment situations: treatment naive or injectables or DMF/
FTY or natalizumab.
Results
Seven hundred thirty-two patients with RRMS (female/male: 2.4:1.0; DMF n = 409, FTY n =
323) were analyzed. Compared with FTY-treated patients, DMF-treated patients discontinued
treatment more frequently mainly because of side effects (DMF/FTY: 29.3%/20.7%). Clinical
relapses occurred in 24.5% of the patients within 24 months. Survival analysis demonstrated
that compared with FTY treatment, DMF treatment was associated with an adjusted hazard
ratio (aHR) for occurrence of relapse of 1.9 (95% CI 1.4–2.6, p < 0.001, n = 732). Stratification
into pretreatment groups unmasked a higher relapse risk in DMF patients pretreated with
natalizumab (aHR [95% CI] 4.5 [1.9–10.8], p = 0.001, n = 122) or to a lesser extend also in
treatment-naive patients (aHR [95% CI] 1.9 [1.01–3.6], p = 0.045, n = 230). No differences
were observed in patients pretreated with injectables or the respective other oral drug
(injectables: p > 0.05, n = 341; other oral: p > 0.05, n = 39).
Conclusions
DMF treatment was associated with higher clinical disease activity compared with FTY
treatment. A subgroup analysis suggested beneficial effects of FTY in treatment-naive and
patients pretreated with natalizumab.
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Fingolimod (FTY) and dimethyl fumarate (DMF) are oral
immunotherapies approved to treat patients with relapsing-
remitting MS (RRMS).1,2 Several studies have retrospectively
compared clinical efficacy between DMF and FTY, demon-
strating mostly a similar efficacy.3–6 Moderate differences
between DMF/FTY were present concerning MRI disease
activity and treatment tolerability, which was superior in FTY-
treated patients. In addition, focusing on the outcome pa-
rameter “no evidence of disease activity-3” (NEDA-3), which
was reached in DMF- and FTY-treated patients with com-
parable frequencies, a subgroup analysis, however, unmasked
a superiority of FTY in patients switching from self-injectable
drugs to the respective oral substance.6 This different clinical
efficacy was not present in treatment-naive patients. Stratifi-
cation into other pretreatment groups (e.g., pretreatment with
natalizumab or the other oral drug) is missing.6
Our study will provide real-world data comparing discontinu-
ation rates and clinical efficacy of DMF and FTY concerning
the following pretreatment situations: treatment naive, inject-
ables, the other oral drug DMF or FTY, and natalizumab.
Methods
Patient groups studied
We conducted a retrospective observational study over 24
months including 732 patients with RRMS of the 4 partici-
pating European centers (figure) who had been treated with
DMF (n = 409) or FTY (n = 323). Identification of eligible
patients was performed using the following search terms “MS
and fingolimod or Gilenya or FTY” in the centers Aarau,
Athens, and Bern and “MS and Tecfidera or dimethyl fuma-
rate or fumarate or DMF” in all 4 participating centers to
search local clinical information systems within the following
time frames for Bern, Aarau, and Athens January 2011–
December 2018 and for Bochum January 2011–January 2016.
No additional selection criteria were set. All patients identified
with this search algorithm were included. MS diagnosis was in
accordance with the 2010 McDonald criteria.7 Definition of
clinical MS relapse followed national guidelines. The follow-
ing variables were extracted from medical records: date of
birth, year of MS diagnosis, sex, previous MSmedication, date
of the adverse event, date of drug withdrawal, date of treat-
ment initiation of DMF or FTY, date of the 1st relapse under
DMF or FTY treatment, or if no relapse during the 2-year
follow-up occurred date of the last follow-up visit.
Statistical analysis
Categorical data are presented as frequencies and continuous
data as means and 95% confidence intervals (95% CI) and
compared using for continuous variables Mann-Whitney test
and for categorical variables χ2 test. Survival analyses with the
outcome “clinical relapse” were performed using Cox re-
gression analysis adjusted for sex, RRMS disease duration, and
region (Switzerland vs Europe). Survival analysis was per-
formed for different pretreatments: (1) treatment naive, (2)
previous treatment with injectables (interferon or glatiramer
acetate), (3) previous treatment with DMF or FTY, or (4)
previous treatment with natalizumab. Level of significance
was set to p < 0.05.
Ethical approvals
The respective ethic committees Aarau (2016-02233), Bern
(2017-01369), Eginition Hospital Athens (1272018-511),
and Bochum (5408-15) approved the analysis.
Data availability
Anonymized source data are available on reasonable request
via the corresponding author.
Results
Baseline demographics are shown in table 1. The primary reason
for beginning with FTY was disease activity (DMF: 71/409,
17.4% vs FTY: 108/323, 33.4%, p < 0.001). Adverse events
during previous immunotherapies were the main reason for
beginning with DMF (DMF: 113/409, 27.6% vs FTY: 58/323,
18.0%, p < 0.001). Drug discontinuation was more common in
DMF- than in FTY-treated patients (DMF: 120/409, 29.3% vs
FTY: 67/323, 20.7%, p = 0.008). Adverse events were the most
common reason for withdrawal (table 1). Despite clinical disease
activity occurred in 20.4%–27.6% (FTY: 66/323 vs DMF: 113/
409) of the patients, in only 33.6%–47.0% (DMF: 38/113 vs
FTY: 31/66) of these patients, disease activity let to FTY/DMF
withdrawal (table 1). The mean time to the 1st relapse was
shorter in DMF-treated patients (years mean [95% CI]: DMF:
0.6 [0.5–0.6], n = 113 vs FTY: 1.0 [0.8–1.1], n = 66; p < 0.001),
and this differences was the highest in the group pretreated with
injectables (years mean [95% CI]: DMF: 0.6 [0.3–0.7], n = 30
vs FTY: 1.1 [0.9–1.3], n = 42; p < 0.001, table 1).
Compared with patients treated with FTY, patients treated
with DMF had a higher adjusted hazard ratio (aHR) for oc-
currence of clinical relapse (aHR [95% CI] 1.9 [1.4–2.6], p <
0.001, n = 732, table 1). Stratification into pretreatment groups
highlighted a higher relapse risk in DMF-treated patients pre-
treated with natalizumab (aHR [95% CI] 4.5 [1.9–10.8], p =
0.001, n = 122, table 1) or to a lesser extent in treatment-naive
patients (aHR [95% CI] 1.9 [1.01–3.6], p = 0.045, n = 230,
table 1). No differences were observed in patients pretreated
Glossary
aHR = adjusted hazard ratio; DMF = dimethyl fumarate; FTY = fingolimod; NEDA-3 = no evidence of disease activity-3;
RRMS = relapsing-remitting MS.
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with injectables or the respective other oral drug (injectables: p
> 0.05, n = 341; other oral: p > 0.05, n = 39, table 1).
Discussion
We present a comparison of discontinuation rates and clinical
efficacy data of DMF- and FTY-treated patients with RRMS
over a follow-up period of 24months. Taking advantage of the
FTY label as 1st-line MS treatment in Switzerland, this study
provides a unique patient population for head-to-head com-
parison of the clinical efficacy of DMF vs FTY in different
pretreatment situations including treatment-naive patients.8
In general, FTY appears to be less frequently withdrawn and
clinically more effective in terms of relapse activity in our
study. This increased clinical efficacy was present in
treatment-naive and in patients pretreated with natalizumab,
whereas patients pretreated with injectables or switching from
DMF to FTY or vice versa demonstrated to have an equal
clinical response to treatment.
In line with previous reports, we demonstrated that discon-
tinuation was more common in DMF- than in FTY-treated
patients with adverse drug events being the main reason for
drug withdrawal.5 Concerning disease activity, previous
studies reported an equal efficacy3,4 or a trend toward a higher
efficacy of FTY compared with DMF.5,6 The latter was also
present in our study; however, our work provides additional
evidence for different drug efficacy in regard to previous im-
munotherapy. Patients switching from natalizumab and to
a lesser degree also treatment-naive patients with MS
benefitted from FTY in terms of the outcome “occurrence of
relapse”, whereas no differences for occurrence of relapses
were seen in patients pretreated with injectables or the re-
spective other oral drug.
Prosperini et al.6 found a superiority of FTY in patients pre-
treated with injectables, whereas—different to ours—this was
not present in treatment-naive patients. Reasons for different
findings may be the different end points used and the different
drug labels of each study country. Prosperini et al.6 in-
vestigated NEDA-3 status, whereas our investigation purely
focused on clinical relapses. Analysis of NEDA-3 status was
not possible in our study because of different MRI protocols,
frequencies of MRI assessments, and clinical visits between
participating centers making a structured end point compar-
ison for MRI and disability readouts prone to centrum biases.
The limitations of our retrospective study will be addressed in
the following. Adjustment of the Cox regression analysis for
each center was not possible because of small patient and
event numbers in each single center, respectively (supple-
mentary table 1, links.lww.com/NXI/A174), creating a limi-
tation of our analysis. We therefore adjusted for region
(Switzerland vs EU), as recommended in such cases by the
European Medicine Agency.9 Adjustment for region is justi-
fied by the country-specific label of FTY considering 1st-
(Switzerland) vs 2nd-line treatment (Europe: Germany and
Greece), which might have had the greatest influence on our
analysis.10 Patients were identified in the centers using pre-
defined terms to search the existing local clinical information
systems (figure). No other selection criteria were set.
Whether in general, the setting of university and large aca-
demic MS centers creates a selection bias, cannot be
Figure Study flowchart
Some patients of this cohort included in (1) Diem et al. TAND 2018 doi: 10.1177/1756286418791103 and (2) Miclea et al. J Neurol 2016 doi: 10.1007/s00415-
016-8175-3. Locally used clinical information systems were i-pdos (Phoenix Technologies, Milpitas) in Bern, Orbis (Agfa HealthCare, Mortsel, Belgium) in
Bochum, in-house “Demyelinating Diseases Database 1st Department of Neurology” in Athens, and KISIM (Cistec AG, Zürich, Switzerland) in Aarau. DMF =
dimethyl fumarate; FTY = fingolimod.
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Table 1 Description of fingolimod (n = 323) or DMF (n = 409) treated patients andCox regressionmodels to predict clinical
disease activity
FTY DMF p Value
N (%) 323 (44.1) 409 (55.9)
Centre, N (%)
Aarau 144/323 (44.6) 48/409 (11.7) NA
Athens 99/323 (30.7) 41/409 (10.0) NA
Bern 80/323 (24.8) 204/409 (49.9) NA
Bochum 0/323 (0.0) 116/409 (28.4) NA
Female, N (%) 226/323 (70.0) 292/409 (71.4) 0.674
Age in years, mean (95% CI) 39.6 (37.5–40.0) 40.0 (38.8–41.2) 0.271
Disease duration in y, mean (95% CI) 6.8 (6.1–7.5) 5.9 (5.7–6.6) 0.001
MS treatment before DMF or FTY, N (%)
Treatment naive 66/323 (20.4) 164/409(40.1) <0.001
Injectables 183/323 (56.7) 158/409 (38.6) <0.001
DMF 12/323 (3.7) NA NA
Fingolimod NA 27/409 (6.6) NA
Natalizumab 62/323 (19.2) 60/409 (14.7) 0.103
Primary reasons for beginning with DMF or FTY, N (%)
PML risk during NTZ 79/323 (24.5) 52/409 (12.7) <0.001
Medication adverse effects 58/323 (18.0) 113/409 (27.6) <0.001
Disease activity 108/323 (33.4) 71/409 (17.4) <0.001
Postpregnancy 1/323 (0.3) 1/409 (0.2) 0.980
Treatment naive 66/323 (20.4) 162/409 (39.6) <0.001
Unknown 11/323 (3.4) 10/409 (2.4) 0.439
Discontinuation of DMF/FTY, N (%) 67/323 (20.7) 120/409 (29.3) 0.008
Disease activity 31/323 (9.6) 38/409 (9.3) 0.888
Medication adverse effects 27/323 (8.4) 64/409 (15.6) 0.005
Pregnancy 4/323 (1.2) 9/409 (2.2) 0.328
Unknown 5/323 (1.5) 9/409 (2.2) 0.522
Mean time to discontinuation of DMF/FTY, y (95% CI) 1.5 (1.2–1.8) 0.8 (0.7–1.0) <0.001
Treatment naive 0.8 (0.5–1.1) 0.7 (0.5–0.9) 0.157
Injectables 2.0 (1.5–2.5) 1.1 (0.7–1.4) 0.005
Other oral (e.g., DMF → FTY) 1.1 (0.5–1.7) 1.0 (0.2–1.7) 0.307
Natalizumab 0.8 (0.3–1.5) 0.8 (0.3–1.1) 0.905
Clinical relapse within 12 mo, N (%) 37/323 (11.5) 95/409 (23.2) <0.001
Clinical relapse within 24 mo, N (%) 66/323 (20.4) 113/409 (27.6) 0.025
Mean time to first relapse in y, mean (95% CI) 1.0 (0.8–1.1) 0.6 (0.5–0.6) <0.001
Treatment naive 0.8 (0.5–1.1) 0.6 (0.5–0.7) 0.375
Injectables 1.1 (0.9–1.3) 0.6 (0.3–0.7) <0.001
Continued
4 Neurology: Neuroimmunology & Neuroinflammation | Volume 7, Number 2 | March 2020 Neurology.org/NN
sufficiently answered, and should be kept in mind when
interpreting our data.
In addition, other limitations are the relatively small sample
size in the group pretreated with DMF or FTY and the
nonstandardized treatment approach within the 4 participat-
ing centers, e.g., different washout periods between medica-
tion switch, different intervals of MRI, and clinical
investigations. However, as we present a real-world study, the
latter limitation, which interferes with data analysis, mainly
reflects the clinical situation of most neurologists treating
patients with MS.
Considering the growing armamentarium of immuno-
therapies for patients with MS and the known effects of
medication withdrawal and switch during MS disease course,
our study, which provides evidence for decision-making
processes, may guide physicians throughout clinically chal-
lenging treatment options.
Study funding
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Table 1 Description of fingolimod (n = 323) or DMF (n = 409) treated patients and Cox regressionmodels to predict clinical
disease activity (continued)
FTY DMF p Value
Other oral (e.g., DMF → FTY) 0.9 (−1.1–3.1) 0.6 (0.1–1.2) 0.865
Natalizumab 0.5 (0.0–3.0) 0.4 (0.2–0.6) 0.979
aHR (95% CI) N p Value
All patients 1.9 (1.4–2.6) 732 <0.001
Treatment naive 1.9 (1.01–3.6) 230 0.045
Injectables 1.5 (0.9–2.5) 341 0.085
Other oral (e.g., DMF → FTY) 1.4 (0.2–8.3) 39 0.736
Natalizumab 4.5 (1.9–10.8) 122 0.001
Abbreviations: aHR = adjusted hazard ratio; DMF = dimethyl fumarate; DMT = disease-modifying treatment; EU = European Union; FTY = fingolimod;
injectables = interferon or glatiramer acetate; NA = not applicable; NTZ = natalizumab; PML = progressive multifocal leukoencephalopathy.
Statistics: for continuous variables, the Mann-Whitney test was used, and for categorical variables, the χ2 test was used. Cox regression was adjusted for sex,
disease duration, and region (Switzerland vs EU). aHRs are displayed for DMF compared with fingolimod. Significant p values are written in bold letters.
Clinical information systems in use were i-pdos (Phoenix Technologies, Milpitas) in Bern, Orbis (Agfa HealthCare, Mortsel, Belgium) in Bochum, in-house
“Demyelinating Diseases Database of 1st Department of Neurology” in Athens, and KISIM (Cistec AG, Zürich, Switzerland) in Aarau.
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